Biophytis sees positive data from PHASE 2-3 COVA CLINICAL STUDY of Sarconeos - Stanislas Veillet , CEO, Biophytis 00:00:00

Share On Facebook Share On Twitter

Biophytis CEO Stanislas Veillet joined Steve Darling from Proactive to share news the company has released the full results from its phase 2-3 COVA clinical study evaluating Sarconeos

Recent Videos